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Dengue virus (DENV) nonstructural protein-1 (NS1) is a secreted glycoprotein that is absent from viral particles but
accumulates in the supernatant and on the plasma membrane of cells during infection. Immune recognition of cell
surface NS1 on endothelial cells has been hypothesized as a mechanism for the vascular leakage that occurs during
severe DENV infection. However, it has remained unclear how NS1 becomes associated with the plasma membrane, as
it contains no membrane-spanning sequence motif. Using flow cytometric and ELISA-based binding assays and mutant
cell lines lacking selective glycosaminoglycans, we show that soluble NS1 binds back to the surface of uninfected cells
primarily via interactions with heparan sulfate and chondroitin sulfate E. DENV NS1 binds directly to the surface of
many types of epithelial and mesenchymal cells yet attaches poorly to most peripheral blood cells. Moreover, DENV
NS1 preferentially binds to cultured human microvascular compared to aortic or umbilical cord vein endothelial cells.
This binding specificity was confirmed in situ as DENV NS1 bound to lung and liver but not intestine or brain
endothelium of mouse tissues. Differential binding of soluble NS1 by tissue endothelium and subsequent recognition
by anti-NS1 antibodies could contribute to the selective vascular leakage syndrome that occurs during severe
secondary DENV infection.
Citation: Avirutnan P, Zhang L, Punyadee N, Manuyakorn A, Puttikhunt C, et al. (2007) Secreted NS1 of dengue virus attaches to the surface of cells via interactions with
heparan sulfate and chondroitin sulfate E. PLoS Pathog 3(11): e183. doi:10.1371/journal.ppat.0030183
Introduction
Dengue hemorrhagic fever and dengue shock syndrome
(DHF/DSS) are severe and potentially fatal complications of
infection by dengue virus (DENV), a mosquito-borne RNA
virus of the Flaviviridae family. Globally, DENV infects 25 to
100 million people per year, but the life-threatening
complications primarily occur in school-age children [1].
Four serotypes of DENV exist, and DHF/DSS is commonly
associated with secondary infection with a different virus
serotype [2,3]. In the most severe cases, clinical deterioration
is characterized by a rapid decline after several days of
continuous high fever, thrombocytopenia, and selective
vascular leakage at serosal sites [4]. The vascular leakage
syndrome results in hemoconcentration, pleural effusions
and ascites, and hypotension [4]. An effective strategy for
disease prevention or treatment is currently lacking.
The pathogenesis of DHF/DSS reﬂects a complex interplay
of the host immune response and the viral determinants of
virulence [5–7]. A model of immunopathogenesis has been
suggested based on an increased risk of DHF with secondary
infection and in children within the ﬁrst year of life born to
DENV-immune mothers [8,9]. From this, the hypothesis of
antibody-dependent immune enhancement of infection
emerged. In support of it, enhancement of DENV infection
in monocytes in vitro with pre-illness serum correlates with
increased risk of DHF in vivo [9,10], and peak viremia is
higher in patients with severe secondary DENV infection [11–
13]. Differences in speciﬁc genetic determinants among viral
isolates [14–16] also modulate virulence, as some DENV
strains fail to cause severe disease [17,18]. A pathologic
cytokine response that occurs after extensive T cell activation
also likely contributes to the syndrome [5]. Elevated levels of
cytokines including IFN-a, TNF- a, and IL-10 correlate with
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low-afﬁnity DENV-speciﬁc T cells produces vasoactive cyto-
kines [25–27]. Finally, accumulation of soluble NS1 in serum
also correlates with disease severity and is believed to
contribute to changes in vascular permeability through
antibody-dependent activation of the complement cascade
[28].
NS1 is a ;48-kDa glycoprotein that is absent from the
infectious viral particle. NS1 is, however, an essential gene
within infected cells, as it functions as a cofactor for viral
RNA replication, colocalizing with the double-stranded RNA
replicative form [29,30]. NS1 is synthesized in an infected cell
as a soluble monomer and rapidly dimerizes after post-
translational modiﬁcation in the lumen of the endoplasmic
reticulum, with subsequent transport to the cell surface and
release into extracellular milieu [31]. In solution, secreted
NS1 behaves as a hexamer [32] and accumulates in serum in
high amounts (up to 50 lg/ml) [11,28,33]. The mechanism(s)
by which soluble and cell surface–associated NS1 contributes
to ﬂavivirus pathogenesis remains uncertain. It has been
proposed to facilitate immune complex formation [28,34],
elicit auto-antibodies that react with platelet and extracel-
lular matrix proteins [35,36], cause endothelial cell damage
via antibody-dependent complement-mediated cytolysis
[35,37–39], directly enhance infection [40], and attenuate
the alternative pathway of complement activation by binding
factor H [41].
The mechanism by which NS1 becomes associated with the
plasma membrane is poorly understood. The protein lacks
amino- or carboxyl-terminal membrane-spanning or anchor-
ing sequences [42]. Although covalent linkage by a glyco-
sylphosphatidylinositol (GPI) anchor to the plasma
membrane of DENV-infected cells has been suggested [43],
this mechanism has not been conﬁrmed. Also, it does not
explain how uninfected, as well as infected cells, accumulate
NS1 on their surfaces. In this study, we demonstrate that
soluble DENV NS1 attaches to uninfected cells primarily via
an interaction with the glycosaminoglycans (GAG) heparan
sulfate (HS) and chondroitin sulfate E (CS-E), and that GAG
sulfation is a critical cellular modiﬁcation necessary for
binding. Moreover, soluble DENV NS1 preferentially binds
subsets of cells including human microvascular endothelial
cells. Our ﬁndings suggest that the selective vascular leakage
that occurs in severe DENV infection may be related to the
relative ability of endothelial cells in different tissues to bind
soluble NS1 and be targeted by cross-reactive anti-NS1
antibodies during secondary infection.
Results
Flavivirus NS1 is a secreted nonstructural glycoprotein that
lacks a membrane-spanning region yet becomes cell surface–
associated [31,42]. As NS1 attachment to the cell surface may
be important for immune recognition [28,44] and immune
evasion [41], we set out to identify the mechanism by which
soluble NS1 binds to the surface of cells. Although it has been
suggested that DENV NS1 attaches to the plasma membrane
via a GPI anchor [43], this is unlikely to explain how DENV
NS1 binds to uninfected cells. To assess this issue in greater
detail, we developed a ﬂow cytometric–based NS1 cell surface
binding assay. We puriﬁed soluble DENV NS1 from the
supernatants of baby hamster kidney (BHK) cells that stably
express a DENV-2 subgenomic replicon (BHK DENV-2 Rep
cells [45]). These cells produce high levels of intracellular
(Figure 1A) and soluble NS1 as determined by a capture
ELISA (3.6 6 0.2 lg/ml of supernatant) and western blot
(unpublished data). Elution proﬁles of puriﬁed NS1 after
immunoafﬁnity or ion exchange chromatography are shown
(Figure 1B and 1C, respectively). The yield of puriﬁed NS1
from BHK DENV-2 Rep cells (Figure 1D) was similar to that
previously obtained from DENV-2-infected cell supernatants
[28] and retained immunoreactivity as judged by western blot
(Figures 1E and S1) or ELISA with a panel of conformation-
ally sensitive anti-NS1 mAbs (unpublished data).
DENV NS1 Selectively Binds to Uninfected Cells of Specific
Lineage
Uninfected cells were tested for the ability to bind soluble
DENV NS1. Incubation with either puriﬁed DENV NS1 or
supernatants from BHK DENV-2 Rep cells resulted in rapid
binding of NS1 to many cell types (Figure 2 and Table 1).
Binding of NS1 to Chinese hamster ovarian epithelial (CHO)-
K1, Vero, and 4/4 RM4 cells was dose-dependent and
saturable, and maximum binding was achieved at a concen-
tration of 20 lg/ml, which is in the range reported in vivo
during secondary infection [11,28]. DENV NS1 bound to the
surface of several types of epithelial and ﬁbroblast trans-
formed cell lines (BHK, CHO-K1, Vero, 293T, HepG2, Hep3B,
and L929) including those of human and nonhuman origin.
NS1 also bound to primary, untransformed cells including
keratinocytes (HaCat, CCD-1102), skin and lung ﬁbroblasts
(Detroit-551 and IMR-90), and freshly isolated tonsillar
epithelial cells.
As high levels of soluble NS1 are detected in the blood of
DHF patients [11,28,33], we extended our analysis to human
peripheral blood cells. Notably, DENV NS1 failed to bind to
the surface of freshly isolated peripheral blood mononuclear
cells or erythrocytes. Similar negative results were obtained
with puriﬁed CD14
þ monocytes, CD19
þ B lymphocytes, and
CD4
þ T lymphocytes. Moreover, DENV NS1 only weakly
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Author Summary
Dengue virus (DENV) is a mosquito-transmitted virus that infects
humans and has become a global emerging infectious disease
threat. Four serotypes of DENV exist, and the most severe cases are
associated with secondary infection with a different virus serotype.
Clinical deterioration is characterized by bleeding and selective
vascular leakage from endothelium in specific tissue sites. An
increased understanding of how DENV proteins contribute to this
phenotype is vital to developing novel vaccines and identifying
individuals at risk for severe disease. DENV nonstructural protein-1
(NS1) is one such protein: during infection, it is secreted and
accumulates in the supernatant and on the surface of cells. In this
study, we demonstrate that soluble DENV NS1 attaches to subsets of
cells, including some but not all endothelial cells, primarily via an
interaction with specific glycosaminoglycans (heparan sulfate and
chondroitin sulfate E). This was confirmed in tissue binding studies
as DENV NS1 bound to lung and liver but not intestine or brain
endothelium. Our findings suggest that the selective vascular
leakage that occurs in severe DENV infection may be related to
the relative ability of endothelial cells in different tissues to bind
soluble NS1 and to be targeted by cross-reactive anti-NS1 antibodies
during secondary infection.bound to the surface of monocyte-derived macrophages. In
contrast to that observed with primary lymphocytes, DENV
NS1 bound strongly to the surface of several malignant T cell
lines, including Jurkat, H9, and EL-4 (Figure 2 and unpub-
lished data).
As vascular leakage is a hallmark of DHF/DSS, and
endothelial cells are believed to be targets of immune-
mediated damage, we analyzed the binding of NS1 to human
endothelial cells. Interestingly, DENV NS1 bound strongly to
human dermal and lung microvascular endothelial cells
(HMEC) and HMEC-lung blood (HEMC-LB), modestly to
aortic endothelial cells, but minimally to primary or
Figure 1. Purification of DENV NS1 from BHK DENV-2 Rep Cells
(A) A flow cytometry histogram of expression of DENV NS1 in BHK DENV-2 Rep cells. Cells were fixed and stained with anti-DENV-2 NS1 mAbs or isotype
control Abs. One representative experiment of three is shown.
(B) Elution profile of purified NS1 after immunoaffinity chromatography of serum-free supernatants of BHK DENV-2 Rep cells. Peak fractions (19–21)
were combined and passed over an ion-exchange column, and purified NS1 was eluted (C) with a linear NaCl gradient (diagonal line).
(D) SDS-PAGE of purified soluble DENV NS1 from BHK DENV-2 Rep cells. Purified NS1 was boiled prior to nonreducing 12% SDS-PAGE and silver staining.
Molecular weight markers are shown at the left.
(E) Immunoreactivity of purified DENV-2 NS1. Western blot analysis of purified DENV-2 NS1 after nonreducing 12% SDS-PAGE was performed using the
2G6 anti-DENV NS1 mAb.
doi:10.1371/journal.ppat.0030183.g001
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Mechanism NS1 Attachment to Cellsimmortalized human umbilical vein endothelial cells (HU-
VEC or Eahy926).
Soluble DENV NS1 Binds to GAG
As our data indicated that soluble DENV NS1 bound a
subset of uninfected mammalian cells of different lineages,
we sought to identify the mechanism of attachment. We
hypothesized that NS1 might interact with a highly conserved
moiety, such as a GAG. To test this, we compared DENV NS1
binding to wild-type CHO-K1 cells and seven different CHO
cell lines (Table 2) that are either defective in GAG biosyn-
thesis or express GAG with distinct structural speciﬁcities.
CHO-745 cells, which genetically lack xylosyltransferase, the
enzyme required for biosynthesis of both HS and CS [46],
showed a 60%–70% reduction (p , 0.0001) in binding of
DENV NS1 (Figure 3A and Table 2). Similarly, CHO-M1 cells,
which are defective in HS biosynthesis [47], exhibited a ;50%
reduction (p ¼ 0.02) in DENV NS1 binding. However, CHO-
H8 cells [48], which are a variant of CHO-M1 HS-deﬁcient
cells overexpressing CS 2-O-sulfotransferase (2-OST) (pro-
ducing a 30-fold increase in double sulfated disaccharide
residues on CS), showed levels of DENV NS1 binding that
were similar to CHO-K1 wild-type cells. Thus, both HS and
CS sustain cell surface binding to DENV NS1, at least on CHO
cells.
To determine if DENV NS1 required modiﬁcation of HS
structures for binding, we tested CHO cell lines that
overexpress different 3-O-sulfotransferases (3-OST) (Figure
3A and Table 2). All 3-OSTs transfer sulfate moieties to the 3-
O-position of N-sulfated glucosamine (GlcNS) and generate a
highly sulfated HS motif with distinct biological properties
(Table 2). CHO-K1.5 cells overexpress 3-OST-1, which adds 3-
O-sulfate to GlcNS in a glucuronic acid (GlcA)-GlcNS 6 6S
sequence context, and facilitate high afﬁnity antithrombin III
binding [49]. CHO-K1.N7 cells overexpress 3-OST-3, which
adds 3-O-sulfate to GlcNS in a GlcA2S/iduronic acid (IdoA)
2S-GlcNS 6 6S sequence context, and promote herpes
simplex virus (HSV) glycoprotein D binding and entry [50].
By contrast, overexpression of 3-OST-5 (CHO-3-OST-5 cells)
adds 3-O-sulfate to GlcNS in both GlcA-GlcNS 6 6S and
GlcA2S/IdoA2S-GlcNS 6 6S sequence contexts. Notably, all
CHO cell lines expressing distinct 3-OST showed enhanced
DENV NS1 binding by 30%–50% (p , 0.05) without a
preference for any of the distinct 3-OST-modiﬁed HS
structures. Thus, unlike other glycoproteins, DENV NS1
Figure 2. DENV NS1 Binds to Cells of Specific Lineages
Dose-dependent binding of DENV NS1 to cell surfaces. Purified DENV NS1 (5, 10, 20, and 40 lg/ml) was added to different cell types at 4 8C for 1 h. After
washing, bound NS1 was detected by anti-NS1 antibody staining and flow cytometry. An example of DENV NS1 binding to CHO-K1 cells using
supernatant from BHK-DENV-2 Rep cells is depicted in the inset at the upper right corner of the top left histogram. Examples of histogram profiles of
DENV NS1 binding to epithelial, fibroblast, hematopoietic, and endothelial cells are depicted. One representative of three experiments is shown. No
specific staining was observed after BSA binding and incubation with an NS1 antibody or NS1 binding and incubation with an isotype-matched control
antibody (unpublished data).
doi:10.1371/journal.ppat.0030183.g002
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Mechanism NS1 Attachment to Cellsprefers highly sulfated HS motifs for binding and does not
require speciﬁc HS sequences.
On CHO cell lines, the speciﬁcity of the GAG had a more
dominant effect on regulating NS1 binding than the absolute
level. Using a previously developed high-pressure liquid
chromatography method [51], we quantiﬁed the amount of
cell surface HS and CS GAG in different CHO cell lines and
compared it to NS1 binding (Table 2). Although CHO-M1
cells expressed twice the amount of total GAG compared to
wild-type CHO-K1 cells, CHO-M1 cells bound NS1 poorly.
Thus, the total level of GAG did not directly correlate with
NS1 binding. Consistent with this, similar amount of GAG
were observed on CHO-K1 and other 3-OST-expressing CHO
cell lines, yet 3-OST-expressing CHO cells bound NS1 more
strongly. Moreover, Vero cells express ;3-fold higher levels
of HS compared to CHO-K1 cells (unpublished data) but
bound NS1 less well compared to CHO-K1 cells (Figure 2 and
Table 2).
A requirement of GAG for DENV NS1 binding to the cell
surface was conﬁrmed independently by enzymatic treatment
of BHK and CHO-K1 cells with speciﬁc heparin lyases and
chondroitinases (Figure 3B). Treatment of BHK or CHO-K1
cells with heparin lyases I, II, and III, which speciﬁcally
remove HS, reduced DENV NS1 binding (;50%–60%, p ,
0.05) to the levels observed in GAG-negative CHO-745 cells.
In contrast, DENV NS1 attachment was not signiﬁcantly
affected by treatment with chondroitinase ABC, which
degrades all types of CS [52]. As expected, treatment with
both enzymes had no effect on DENV NS1 binding to CHO-
745 cells, which lack GAG. Nonetheless, a small amount of
NS1 binding to CHO-745 cells was observed, presumably
through a subordinate GAG-independent pathway. Overall,
the analysis of CHO cell mutants and enzymatic treatments
suggested that HS and highly sulfated forms of CS were the
primary cell surface GAG that sustained DENV NS1 binding
on CHO and BHK cells.
As an additional conﬁrmation, we performed competitive
binding assays with soluble GAG. Pre-incubation with soluble
CS-E or heparin (HP) substantially decreased (;50%, p ,
0.005), in a dose-dependent manner, DENV NS1 binding to
BHK cells (Figure 4A–4C). Small, albeit signiﬁcant inhibition
(;15%, p , 0.05), was observed even at relatively low
concentrations CS-E and HP (0.01 lg/ml or 0.033 nM). In
contrast, CS-A and -B inhibited NS1 binding only at higher
concentrations (100 lg/ml or 3.3 lM, p , 0.05) whereas CS-C
and -D showed no signiﬁcant effect (p . 0.2). Similarly, pre-
incubation with CS-E and HP reduced DENV NS1 attachment
to HMEC cells (;40%, 0.01 lg/ml, p , 0.01) (Figure 4D–4F). In
a more direct in vitro binding ELISA, an interaction between
DENV NS1 and HS or CS-E was established, whereas only
Table 1. DENV NS1 Binds to a Variety of Cell Types
Cell Type Cell Description Mean Fluorescent Intensity p-Value
No DENV NS1 þ
Anti-NS1 mAb
DENV NS1 þ
Isotype Control mAb
DENV NS1 þ
Anti-NS1 mAb
BHK Hamster kidney fibroblast 5.4 6 0.3 4.1 6 0.5 55.4 6 4.9 ,0.0001
CHO-K1 Chinese hamster ovarian epithelium 4.5 6 0.3 3.8 6 0.6 45.0 6 4.6 ,0.0001
Vero Monkey kidney epithelium 3.3 6 0.1 3.6 6 0.3 26.2 6 8.2 ,0.05
293T Human kidney epithelium 3.8 6 0.2 3.1 6 0.1 17.9 6 1.1 ,0.0001
IMR-90 Human lung fibroblast 4.0 6 0.4 3.6 6 0.7 44.6 6 2.5 ,0.0001
Detroit-550 Human skin fibroblast 3.4 6 0.7 3.6 6 0.5 21.6 6 4.7 ,0.005
CCD-1102 Human keratinocytes 3.5 6 0.4 3.0 6 0.2 33.9 6 3.2 ,0.0001
HepG2 Human hepatocellular carcinoma 4.2 6 0.6 3.5 6 0.5 96.2 6 11.6 ,0.0001
4/4 RM4 Rat visceral mesothelium 4.2 6 0.1 4.0 6 0.9 11.3 6 0.8 ,0.005
HUVEC 1 8 human umbilical cord vein EC 3.4 6 0.1 3.5 6 0.1 4.6 6 0.2 ,0.05
HMEC Human dermal microvascular EC 3.8 6 0.2 3.6 6 0.1 34.9 6 1.9 ,0.0001
HMEC-LB 1 8 Human lung blood
microvascular EC
5.0 6 0.4 4.6 6 1.0 21.2 6 0.7 ,0.0001
HAEC 1 8 Human aotic EC 3.9 6 0.2 ND 12.5 6 0.7 ,0.001
Eahy926 Human umbilical cord vein EC 3.7 6 0.1 3.1 6 0.2 5.2 6 0.5 ,0.05
U937 Human monocytic cell 3.8 6 0.2 2.8 6 0.1 4.8 6 0.9 0.12
MEG-01 Human megakaryoblast 4.9 6 0.4 3.1 6 0.5 11.7 6 2.0 ,0.05
Human monocytes Peripheral blood 3.5 6 0.1 2.0 6 0.4 4.4 6 0.5 0.34
Human macrophages Peripheral blood
a 5.9 6 0.0 5.6 6 1.3 9.8 6 0.9 ,0.05
Human platelets Peripheral blood 2.2 6 0.2 ND 1.9 6 0.2 0.29
Human CD19
þ B lymphocytes Peripheral blood 5.5 6 0.6 ND 6.7 6 0.5 0.21
Human CD4
þ T lymphocytes Peripheral blood 5.1 6 0.1 ND 4.9 6 0.3 0.59
Human peripheral blood
mononuclear cells
Peripheral blood 4.3 6 0.6 3.6 6 0.7 5.8 6 0.6 0.06
Human erythrocytes Peripheral blood 4.2 6 0.4 3.2 6 0.6 5.4 6 0.3 0.08
Cells were incubated with serum-free supernatants from BHK DENV-2-Rep (DENV NS1) or BHK (negative control, No DENV NS1) cells for 1 h at 4 8C. Bound DENV NS1 was detected by anti-
DENV NS1 mAb (2G6) followed by secondary antibody. Analysis was performed on gated viable cells (10, 000 events) by flow cytometry. Data are mean 6 SD of three independent
experiments. p-Values were determined by a one-way ANOVA test after comparing the MFI of the cells after incubation with control protein or DENV NS1 with anti-NS1 antibody or DENV
NS1 with isotype control antibody. Among these cell types, BHK, Vero, 293T, HepG2, HUVEC, Eahy926, U937, monocytes, and macrophages can be infected with highly passaged (e.g.,
strains 16681 or New Guinea C) DENV-2 isolates [73]. However, only a subset of cells (BHK, Vero, HepG2, and monocytes) are infected with primary DENV-2 isolates [73].
aMacrophages were generated from peripheral blood monocytes cultured for 7 d in medium containing 50 ng/ml of GM-CSF.
HAEC, human aortic endothelial cell; ND, not determined.
doi:10.1371/journal.ppat.0030183.t001
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Mechanism NS1 Attachment to Cellsweak or no appreciable binding was detected with CS-A, -B,
-C, and -D (Figure 5). Taken together, these results suggest
that NS1 interacts more strongly with HP, HS, and CS-E and
more weakly with CS-A and CS-B. CS-A consists of mainly
GlcA-GalNAc4S repeating disaccharides, CS-B contains both
IdoA-GalNAc4S and GlcA-GalNAc4S as dominant repeating
disaccharides, and CS-C consists of mainly GlcA-GalNAc6S
repeating disaccharides. CS-D and CS-E are enriched in
disulfated disaccharides, GlcA2S-GalNAc6S and GlcA-Gal-
NAc4S6S, respectively. CS-E is unique, as two sulfates are
present in the same GalNAc residue compared to other CS,
and suggests that clustered sulfates rather than net negative
charge on the disaccharide backbone facilitate DENV NS1
binding.
GAG Sulfation Is Critical for DENV NS1 Cellular Attachment
The speciﬁcity of GAG-protein interactions often depends
on the position and degree of sulfation (reviewed in [53–55]).
To clarify if GAG sulfation is required for cell binding of
DENV NS1, we treated BHK and CHO-K1 cells with the
reversible sulfation inhibitor, sodium chlorate [56] (Figure 6A
and 6B). This treatment did not alter cell viability, as analyzed
by propidium iodide exclusion (unpublished data). However,
binding of DENV NS1 to BHK cells was abolished by the
addition of sodium chlorate (.5 mM). In contrast, at
comparable doses, DENV NS1 binding to wild-type CHO-K1
was reduced to the level observed with CHO-745 cells lacking
GAG. Importantly, the phenotype was reversed by the
addition of excess exogenous (10 mM) sodium sulfate (Figure
6C and 6D). Thus, GAG sulfation is required for optimal
binding of soluble DENV NS1 to cells.
Expression of DENV NS1 on the Surface of DENV-Infected
Cells Is Largely GAG-Independent
Although our data suggests that soluble DENV NS1 binds to
the cell surface of uninfected cells via HS and CS-E, we
evaluated if this was the dominant mechanism of attachment
of NS1 to DENV-infected cells. Previous studies have
suggested that ﬂavivirus NS1 may be displayed on the cell
surface of infected cells by a GPI anchor or transmembrane
linkage [43], even though the protein lacks anchor attachment
sequences or consensus membrane spanning domains. To
evaluate this, BHK cells were infected with DENV-2 and
cultured in the presence of high concentrations of soluble
HP. No reduction of DENV NS1 surface expression on
infected cells was observed (Figure 7A). These results were
conﬁrmed by studies with the sulfate inhibitor, sodium
chlorate. In contrast to the inhibitory effect of sodium
chlorate on soluble NS1 binding (Figure 6), no reduction of
DENV NS1 expression on the surface of infected BHK cells
was observed (Figure 7B). Similar studies with BHK DENV-2
Rep cells also showed no change in surface NS1 expression
after sodium chlorate treatment (Figure 7C). Finally, in direct
contrast to that observed with soluble NS1 and uninfected
cells (Figure 3B), treatment of DENV-infected cells with
heparin lyases and/or chondroitinase ABC did not decrease
Table 2. Description of Wild Type and Mutant CHO Cells
Cell
Type
Description GAG Phenotype Biological Effects Surface GAG Quantity
(lg/1 3 10
7 cells)
a
Specific DENV
NS1 Binding
b
K1 Wild type 70% HS and 30% CS Binds to many HS binding proteins
but does not possess special GAG
biological activities requiring
HS 3-O-sulfation or CSE-like
structures [49,50]
HS: 8 6 0.3
CS: 12 6 1( n ¼ 5)
19 6 6
K1.5 Overexpresses
3-O-sulfotransferase-1
Six 3-O-sulfated GlcNS residues
in GlcA-GlcNS 6 6S
per HS chain (;200 repeating
disaccharides per CHO HS chain)
HS that binds antithrombin III [49] HS: 7
CS: 5 (n ¼ 1)
26 6 5
K1.N7 Overexpresses
3-O-sulfotransferase-3
Twelve 3-O-sulfated GlcNS residues
in IdoA2S/GlcA2S-GlcNS
6 6S context per HS chain
HS that binds HSV glycoprotein gD
and allows
HSV-1 entry [74,75]
HS: 7
CS: 7 (n ¼ 1)
29 6 12
PPP6 Overexpresses 3-O-a n d
6-O-sulfotransferase-1
Six 3-O-sulfated GlcNS residues
per HS chain with increased
6-O-sulfated GlcNAc residues
HS that binds antithrombin III [49] ND 25 6 10
3OST5–1 Overexpresses
3-O-sulfotransferase-5
3-O-sulfation occurs on both
GlcA-GlcNS 6 6S and
IdoA2S/GlcA2S –GlcNS 6 6S
sequence context
HS that binds both antithrombin
and HSV-1 glycoprotein gD [61,70]
HS: 7
CS: 5 (n ¼ 1)
24 6 7
M1 Defective in N-acetylglucosaminyl
transferase/glucuronyl transferase
3-fold increase in CS biosynthesis HS-deficient [47] HS: 2 6 0.2
CS: 28 6 2( n ¼ 2)
11 6 4
H8 Overexpresses CS
2-O-sulfotransferase
in M1
30% repeating disaccharides contain
GlcA/IdoA2S-GalNAc4S residues
Binding to heparin co-factor II [48] HS: 0.9 6 0.1
CS: 24 6 3( n ¼ 4)
18 6 9
745 Defective in xylosyltransferase Fails to assemble the first HS
and CS linkage tetrasaccharide
GAG-deficient, lacking both HS
and CS [46]
HS: 2 6 0.1
CS: 4 6 0.1 (n ¼ 2)
7 6 2
aCHO cell variants were cultured as described in Materials and Methods. Surface GAG levels were determined by a published high-pressure liquid chromatography method [51]. The data
are derived from between one and five independent experiments and the standard deviations were from varying numbers (n) of independent GAG isolations.
bDENV NS1 binding was performed as described in Figure 2. The MFI of DENV NS1 binding is derived from the difference in MFI values of cells incubating with and without DENV NS1.
Data are the mean of three independent experiments 6 SD.
doi:10.1371/journal.ppat.0030183.t002
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Mechanism NS1 Attachment to Cellssurface expression of NS1 (Figure 7D). Thus, NS1 expressed
on the surface of infected cells is not modulated by GAG
expression and must attach by an independent mechanism.
Soluble DENV NS1 Binds Selectively to Endothelium In
Situ
Soluble NS1 has been hypothesized to contribute to DHF
pathogenesis by promoting vascular leakage [28,34], which
occurs predominantly into pleural and peritoneal cavities [4].
Our cell culture experiments indicated that soluble DENV
NS1 binds selectively to subsets of human endothelial cells.
We hypothesized, that in vivo, a preferential interaction of
DENV NS1 with speciﬁc endothelium could contribute to
tissue-speciﬁc vascular leakage after immune recognition.
This mechanism would not require direct DENV infection of
endothelial cells, which has been difﬁcult to establish in vivo
by pathological criteria [57,58].
To assess this, sections of uninfected mouse tissues were
incubated with soluble DENV NS1 and analyzed by immuno-
ﬂuorescence and confocal microscopy. Histological analysis
was performed on parallel hematoxylin and eosin–stained
sections (unpublished data). Speciﬁc NS1 binding to endo-
thelial cells lining blood vessels of lung and liver was
observed, based on costaining with mAbs against DENV
NS1 and the endothelial cell–speciﬁc marker CD31 (Figure
8A and 8B). Differences in the pattern of DENV NS1 binding
within the same organ were also observed. For example,
DENV NS1 bound primarily to endothelial cells lining vessels
along the bronchial tree, yet bound poorly to those lining
alveolar capillaries. Strong binding of DENV NS1 to the cells
lining the outer layer of the adventitia of pulmonary vessels
was also apparent (Figure 8A). In the liver, hepatic arteriolar
and sinusoidal endothelial cells bound DENV NS1 weakly,
whereas those within central veins showed strong binding
(Figure 8B). As controls, no appreciable staining was observed
if sections were incubated with bovine serum albumin (BSA)
followed by anti-NS1 mAbs or with puriﬁed DENV NS1 and
isotype control mAbs. The selectivity of soluble NS1 binding
to endothelium in situ was also demonstrated by an absence
of NS1 binding to endothelium in the large intestine (Figure
8C) and brain (unpublished data) of mice. Finally, binding of
DENV NS1 to endothelium in situ also was conﬁrmed in
human lung tissues (Figure 9).
Next, soluble GAG and DENV NS1 competitive binding
assays were performed on lung tissues and images were
analyzed by confocal microscopy and Volocity software. Pre-
incubation of DENV NS1 with soluble CS-E or HP reduced
binding to lung endothelium in situ (CS-E: ;40%, p , 0.0001;
HP: ;30%, p ¼ 0.0002). In contrast, CS-C marginally
decreased DENV-NS1 attachment to lung endothelium
(;8%, p ¼ 0.18). Signiﬁcant binding of DENV NS1 to serosal
surfaces of the lung (pleura) and intestine (peritoneum) was
also observed (Figure S2A and S2B). Based on histological
analysis, mesothelial cells were also targets for DENV NS1
binding in the lung and intestine. Binding of DENV NS1 to
mesothelial cells was speciﬁc as negative results were obtained
when the sections were incubated with NS1 followed by
isotype control mAbs or without NS1 followed by anti-NS1
mAbs. In competitive binding experiments, soluble HP and
CS-E, but not CS-C, also decreased DENV NS1 binding to
lung mesothelial cells (unpublished data).
Discussion
In this study, we demonstrate that soluble DENV NS1 binds
to a subset of uninfected cells via interactions with GAG,
primarily HS and CS-E. In cell culture, NS1 bound strongly to
epithelial cells and ﬁbroblasts, and weakly, if at all, to freshly
isolated human peripheral blood leukocytes. Substantial
variability was observed in NS1 binding to cultured endothe-
lial cells and endothelium in situ. Experiments with the
Figure 3. Binding of DENV NS1 to Cell Surface Is GAG-Dependent
(A) DENV NS1 binding to wild type (K1) and seven mutant CHO cell lines
that overexpress (K1.5, K1.N7, PPP6, and 3OST5–1) or are defective (M1,
H8, and 745) for specific enzymes in GAG synthesis. Binding and staining
were performed at 4 8C and analyzed by flow cytometry. Data are
expressed as the specific MFI of staining after subtraction of background
antibody binding in the absence of NS1. The error bars indicate standard
deviation (SD) corresponding to three independent experiments.
Asterisks note NS1 binding that is statistically different from the CHO-
K1 wild-type cells (* p , 0.05, ** p , 0.005).
(B) Cell surface HS and CS were enzymatically removed from BHK or wild-
type CHO-K1 cells after treatment with a mixture of heparin lyases I, II, III
(H. lyases) or chondroitinase ABC (ABCase) and assayed for binding of
DENV NS1. A GAG-negative mutant cell (CHO-745) was used as a
negative control. Analysis was performed by flow cytometry. Data are
expressed as the specific MFI of staining after subtraction of background
antibody binding in the absence of NS1. The error bars indicate SD
corresponding to three independent experiments. Asterisks indicate
DENV-2 NS1 binding that is statistically different from untreated cells (* p
, 0.05, ** p , 0.005).
doi:10.1371/journal.ppat.0030183.g003
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Mechanism NS1 Attachment to Cellssulfation inhibitor sodium chlorate established that highly
sulfated forms of GAG are required for optimal binding of
soluble DENV NS1. Finally, our experiments suggest that NS1
on the surface of DENV-infected cells is linked primarily by a
distinct, GAG-independent mechanism.
Two major types of GAGs, HS and CS, are produced by
cells in the form of proteoglycans as linear polymers of
repeating disaccharides of uronic acids and glucosamines or
galactosamines. For HS, sulfation of glucosamine and uronic
acid moieties may occur in a clustered manner to generate
highly sulfated domains or in a dispersed pattern to generate
less sulfated or non-sulfated domains. Moreover, GlcNS,
IdoA, and GlcA can be sulfated at multiple positions.
Differential sulfation of GAG results in preferential binding
of growth factors, cytokines, chemokines, enzymes, extra-
cellular matrix, and other proteins to these structures [59].
Cell type–speciﬁc expression of GAG modifying enzymes and
proteoglycan core proteins results in the display of unique
GAG structures on different types of cells [60]. Consistent
with this, our studies demonstrate that DENV NS1 binding to
GAG occurs in a cell type–speciﬁc manner.
The speciﬁcity of GAG interactions is determined by the
pattern of the disaccharide units, the degree of sulfation, and
the spacing of basic amino acid residues in GAG-binding
domains of ligands (reviewed in [53–55]). We observed that
highly sulfated GAG, including HS, HP, and CS-E, demon-
strated the strongest binding for soluble DENV NS1. The use
of mutant CHO lines expressing different levels and forms of
GAG established that speciﬁc HS and CS structures modiﬁed
by 2-O and 3-O-sulfotransferases promoted DENV NS1
binding to cell surfaces. These results are analogous, although
not identical, to studies with HSV glycoprotein D, which show
enhanced cell surface binding when HS is modiﬁed by some,
but not all 3-OST [50,61]. Sulfation was critical for soluble
DENV NS1 binding to cell surfaces, especially for BHK cells,
Figure 4. Soluble HP and CS-E Block DENV NS1 Binding to the Surface of BHK and HMEC
DENV NS1 was incubated with three concentrations of indicated soluble GAG prior to incubation with (A–C) BHK or (D–F) HMEC. DENV NS1 was
detected by flow cytometry (as described in Figure 2). Data are expressed as the specific MFI of staining as described in Figure 3. The error bars indicate
SD corresponding to three independent experiments. Asterisks denote NS1 binding that is statistically different from untreated cells (* p , 0.05, ** p ,
0.005). Examples of histogram profiles in which soluble HP and CS-E at 1 lg/ml concentration block DENV NS1 binding to the surface of (B–C) BHK and
(E–F) HMEC are depicted.
doi:10.1371/journal.ppat.0030183.g004
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Mechanism NS1 Attachment to Cellsas treatment with the sulfate inhibitor sodium chlorate
abolished DENV NS1 attachment.
Also consistent with our results, CS-E, but not CS-A, -B, or
-C, interfered with HSV binding to the target cells [62]. Using
radioactive binding or gel mobility shift assays, we observed
similarly strong binding between West Nile virus NS1 and HS
or CS-E (L. Zhang, K. Chung, and M. Diamond, unpublished
data). As binding of soluble DENV NS1 to GAG requires
sulfation, it is plausible that the interaction is primarily
electrostatic in nature and depends on the relative degree of
negative charge on a GAG motif. The major repeating
disaccharides in HP are IdoA2S-GlcNS6S (;2.7 sulfates/
disaccharides), whereas the major repeating disaccharides in
CS-D and CS-E are GlcA2S-GalNAc6S and GlcA-GalNAc4S6S,
respectively (;1.7 sulfates/disaccharide) [62]. Because NS1
preferentially interacts with CS-E and HP compared to CS-D,
we hypothesize that NS1 binding may prefer closely spaced
sulfates within the same sugar residue. Since HP and CS-E
have distinct sugar sequences, the combination of disacchar-
ide unit and position of sulfation on an individual GAG may
determine the strength of DENV NS1 binding.
The linear sequences XBBXBX and XBBBXXBX (where B is
a basic Arg or Lys amino acid) are common HP binding
motifs in proteins [55]. However, GAG binding sites may not
be exclusively deﬁned by linear sequences but also can
include conformational epitopes that juxtapose basic amino
acids from different segments of a protein [55]. Amino acid
sequence analysis of DENV NS1 reveals no apparent canon-
ical GAG binding motifs. Although reverse genetic strategies
are planned, the identiﬁcation of the amino acids involved in
GAG recognition may await solution of the NS1 structure.
Our data showing that soluble NS1 can bind to the surface
of the GAG-deﬁcient line, CHO-745, albeit at signiﬁcantly
lower levels, suggest that additional molecules also serve as
ligands for DENV NS1 attachment. This secondary attach-
ment ligand may be expressed only on subsets of cells as
addition of sodium chlorate completely abrogated soluble
NS1 binding to BHK cells. Consistent with this, soluble HS
and CS-E only partially reduced DENV NS1 binding to
HMEC. Thus, different cell types may express multiple
ligands for attachment of soluble DENV NS1.
The expression of NS1 on the surface of DENV-infected
cells was insensitive to treatments that reduce GAG levels.
This also suggests the existence of an alternate mechanism of
cell surface NS1 attachment. Some have speculated that a
transmembrane form of NS1 exists, although the protein
sequence lacks a canonical hydrophobic membrane-spanning
domain [42]. Others have postulated that at least some
fraction of cell surface NS1 is linked via a GPI anchor [43,63].
Based on our data, we hypothesize that DENV NS1 is
expressed on cell surfaces by at least two mechanisms: on
uninfected cells soluble NS1 binds to the surface via a GAG-
dependent and GAG-independent mechanism, whereas on
infected cells NS1 attaches via a GAG-independent mecha-
nism, possibly via a membrane or GPI anchor. What remains
uncertain, and is a direction for future research, is whether
the mechanism of cell surface attachment of NS1 has unique
functional consequences, especially in terms of immune
recognition or evasion.
Our studies demonstrate that soluble DENV NS1 differ-
entially binds to cultured endothelial cells in vitro and
endothelium in situ in human and mouse tissues. In contrast,
others have shown that intravenous injection of C57BL/6 x
SJL mice with high concentrations (250 lg/ml) of soluble
DENV-1 NS1 results in binding to and accumulation in
hepatocytes but not to other cell types in the liver or other
tissues [40]. A possible reason for the disparity in results is
that the route of antigen administration may modulate NS1
binding: intravenous injection could prompt rapid ﬁrst-pass
clearance of antigen by the liver. Although further studies are
necessary, our data are consistent with speciﬁc GAG
modiﬁcation by subsets of endothelial cells in different
tissues modulating the level of bound NS1. Indeed, tissue-
speciﬁc expression of different isoforms of enzymes in GAG
biosynthesis has been reported [64,65]. Selective IL-8 binding
to endothelial cells has been observed [66] and could be due
to subtle differences in the display of GAG on the surface of
cells. In favor of this hypothesis, IL-8 selectively binds to
subsets of HP and HS [67].
The pathologic mechanism underlying selective vascular
leakage at serosal sites during DHF/DSS [4] remains unknown.
High levels of intravascular soluble NS1, as observed in
DENV-infected patients, could promote binding and surface
expression of NS1 on selective endothelium without a
requirement for direct viral infection, which has been
difﬁcult to establish histopathologically in fatal DHF cases
[57,58]. In addition, speciﬁc binding to mesothelial cells that
line pleura and peritoneum, as observed in our DENV NS1
binding experiments in situ, could contribute to the pleural
effusions or ascites that are observed in DHF/DSS patients.
Although more experiments are necessary, preferential
binding of soluble NS1 to subsets of endothelial and
mesothelial cells in vivo could lead to tissue-speciﬁc vascular
leakage that occurs during severe secondary DENV infection
after recognition by anti-NS1 antibodies, immune complex
formation, and inﬂammatory damage [28,68].
Figure 5. Direct Binding of DENV NS1 with HS and CS-E
Microtiter plates were coated with indicated soluble GAG overnight at 4
8C. After incubation with supernatants from BHK-DENV-2-Rep cells or
control BHK cells, bound DENV NS1 was detected using DENV NS1–
specific mAbs, followed by biotin-conjugated anti-mouse IgG and HRP-
conjugated streptavidin. Plates were read at an optical density of 450 nm
on a 96-well plate reader. Data are the mean 6 SD from four
independent experiments. Asterisks denote NS1 binding that is statisti-
cally different from binding to background (* p , 0.05, ** p , 0.005). O.
D., optical density.
doi:10.1371/journal.ppat.0030183.g005
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Reagents. CS-A, -B, -C, -D, -E, HP, HS, heparin lyases I, II, and III,
chondroitinase ABC, anti-heparin lyase-digested HS (3G10), and anti-
chondroitinase ABC-digested CS (2B6) antibodies were all purchased
(Seikagaku). DENV-2 NS1–speciﬁc monoclonal antibodies (mAb
hybridomas 2G6, 1A4, 1B2, 1F11, 2E3, and 2E11 [69], and unpublished
data) were puriﬁed by protein G afﬁnity chromatography. Mouse
polyclonal anti-DENV-2 NS1 was produced after BALB/c mice were
intraperitoneally immunized three times with puriﬁed DENV-2 NS1
(10 lg/dose) at a 2-wk interval. Mice were subsequently treated with
pristane followed by injection with myeloma cells to induce ascites
formation. Ascites ﬂuid containing anti-NS1 polyclonal antibody was
collected, and antibodies were puriﬁed by protein-G afﬁnity
chromatography. Anti-mouse IgG conjugated with Alexa Fluor 647,
Alexa Fluor 488, or Cy3 were purchased from Invitrogen. Sodium
chlorate and sodium sulfate were obtained commercially (Sigma).
Cell culture. The following transformed cell lines were obtained
from the ATCC: BHK ﬁbroblasts cells, African green monkey Vero
cells, HEK-293T human embryonic kidney carcinoma cells, L929
mouse ﬁbroblasts, IMR-90 human lung ﬁbroblasts, Detroit-550
human skin ﬁbroblasts, CCD-1102 human keratinocytes, HepG2
and Hep3B human hepatocellular carcinoma cells, 4/4RM4 rat lung
mesothelial cells, Eahy926 HUVEC, MEG-01 human megakaryoblast
cells, Jurkat human leukemic T lymphoblasts, H9 human T lymphoma
cells, EL-4 mouse T lymphoma cells, and U937 human myelomono-
cyte cells. HMEC and keratinocytes (HaCat) were gifts (M. Caparon).
Wild-type CHO-K1 cells and CHO mutant lines with altered GAG
expression (CHO-745, CHO-M1, CHO-H8, CHO-K1.5, CHO-K1.N7,
CHO-3OST5–1, and CHO-PPP6) have been described previously [46–
49,61,70]. BHK, Vero, 293T, L929, and HaCat cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 50 mM HEPES, 4 mM L-glutamine, 100
units/ml penicillin G, and 100 lg/ml streptomycin sulfate. IMR-90,
Detroit-551, HepG2, and Hep3B were grown in minimum essential
Eagle’s medium with Earle’s BSS, 10% FBS, 1% non-essential amino
acids (NEAA), 1 mM sodium pyruvate, 2 mM L-glutamine, 100 units/
ml penicillin G, and 100 lg/ml streptomycin sulfate. CCD-1102 cells
were grown in keratinocyte serum-free medium supplemented with
keratinocyte growth factors (Invitrogen). MEG-01, U937, Jurkat, and
Figure 6. Sulfation Is Required for Soluble DENV NS1 Binding to Cells
(A–B) BHK, wild-type CHO-K1, and GAG-deficient mutant CHO-745 were cultured overnight in sulfate-free medium in the presence of indicated amounts
of sodium chlorate. Cells were harvested and tested for NS1 binding by flow cytometry as described in Figure 2. No appreciable cell death was observed
by this treatment as judged by exclusion of propidium iodide. Data (A) are expressed as the specific MFI of staining as described in Figure 3. The error
bars indicate SD corresponding to three independent experiments. Asterisks denote NS1 binding that is statistically different from untreated cells (** p
, 0.005)
(C–D) Addition of sodium sulfate (10 mM) restores binding of NS1 to cells. Cells were cultured overnight in sulfate-free medium and 25 mM sodium
chlorate with or without 10 mM sodium sulfate (as indicated). Cells were processed for DENV NS1 binding and analyzed by flow cytometry (see Figure
2). Data (C) are expressed as the specific MFI of staining as described in Figure 3. The error bars indicate SD corresponding to three independent
experiments. Asterisks denote NS1 binding that is statistically different from untreated cells (** p , 0.005).
doi:10.1371/journal.ppat.0030183.g006
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Mechanism NS1 Attachment to CellsH9 were cultured in RPMI 1640 medium with 10% FBS, 2 mM L-
glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 100 units/ml
penicillin G, and 100 lg/ml streptomycin sulfate. EL-4 cells were
propagated in Iscove’s medium supplemented with 10% FBS, 1%
non-essential amino acids, 2 mM L-glutamine, 1 mM sodium
pyruvate, 100 units/ml penicillin G, and 100 lg/ml streptomycin
sulfate. HMEC were grown in MCDB 131 (Invitrogen) supplemented
with 10% FBS, 2 mM L-glutamine, 0.3% NaHCO3,1lg/ml hydro-
cortisone (Sigma), 10 ng/ml epidermal growth factor (Sigma), 100
units/ml penicillin G, and 100 lg/ml streptomycin sulfate. All CHO
cell lines were grown in Ham’s F12 medium containing 10% FBS, 100
units/ml penicillin G, and 100 lg/ml streptomycin sulfate, except for
CHO-30ST5–1 cells, which were cultured in CHO medium supple-
mented with 400 lg/ml of G418 sulfate (Cellgro).
Primary human tonsil epithelial cells were isolated according to a
published protocol [71] and cultured in keratinocyte serum-free
medium supplemented with keratinocyte growth factor (Invitrogen).
Primary HMEC-LB and aortic endothelial cells were purchased from
Clonetics (Cambrex Bio Science) and maintained according to the
manufacturer’s protocol. HUVEC were grown in RPMI 1640
containing 10% FBS on 1% gelatin-coated surfaces. Primary human
peripheral blood mononuclear cells were isolated from buffy coats
obtained from the blood bank or healthy volunteers by Ficoll-
Hypaque (Pharmacia) density gradient centrifugation. Human CD14
þ
monocytes, CD19
þ B cells, CD4
þ T lymphocytes were puriﬁed from
primary human peripheral blood mononuclear cells via positive
selection using antibody-coated magnetic beads (Miltenyi Biotec). To
generate macrophages, monocytes were cultured for 7 d in RPMI
1640 supplemented with 50 ng/ml of GM-CSF, 10% FBS, 2 mM
glutamine, 1% nonessential amino acids, 1% sodium pyruvate, 100
units/ml penicillin G, and 100 lg/ml streptomycin sulfate. Human
platelets were isolated from whole blood of healthy volunteers. After
centrifugation at 750 x g for 20 min at 22 8C, platelet-rich plasma was
collected and centrifuged at 1,200 x g for 15 min at 22 8C to obtain
platelets. Human erythrocytes were obtained from healthy donors
following a published protocol [72]. All primary cells were cultured
for ﬁve or fewer passages for the NS1 binding experiments.
Puriﬁcation of DENV NS1. BHK cells that stably propagate a
DENV-2 subgenomic replicon (BHK DENV-2 Rep cells [45]) were
grown to 80%–90% conﬂuence in DMEM containing 10% FBS and 3
lg/ml puromycin (Sigma). Cell monolayers were washed several times
with DMEM and the cells were cultured for another 3 d in serum-free
DMEM supplemented with 3 lg/ml puromycin. DENV NS1 secreted in
the supernatants of BHK DENV-2 Rep was quantiﬁed by NS1 capture
ELISA as previously described [28]. Supernatants were collected,
centrifuged, pooled, and passed through a 0.2-lm ﬁlter prior to
immunoafﬁnity chromatography with anti-NS1 mAb 2G6 [28]. Peak
elution fractions were combined, diluted 7-fold with 20 mM Tris (pH
8.0), and loaded onto a 1-ml Mono Q ion exchange column (GE
Healthcare) at a rate of 1 ml/min. The protein was eluted with a linear
Figure 7. Expression of DENV NS1 on the Surface of Infected Cells Is Not Dependent on GAG
(A) BHK cells were infected with DENV-2 at the MOI of 3 and cultured for 24 h in the presence of indicated concentrations of soluble HP or CS-C. Cells
were then harvested for analysis of surface NS1 expression.
(B) BHK cells were infected with DENV-2 at the MOI of 3 and cultured for 24 h in the presence of 25 mM sodium chlorate. DENV NS1 expression was
determined and analyzed by flow cytometry using anti-DENV NS1 mAb (2G6) or polyclonal anti-DENV NS1.
(C) BHK DENV-2 Rep cells were cultured in medium containing 25 mM sodium chlorate for 48 h. Expression of NS1 on the cell surface was determined
by using anti-DENV NS1 mAb (2G6) and analyzed by flow cytometry.
(D) BHK cells were infected with DENV-2 at the MOI of 3. At 24 h after infection, the cells were treated with a mixture of heparin lyases I, II, III (H. lyases)
or chondroitinase ABC (ABCase). NS1 expression was analyzed by flow cytometry using the 2G6 anti-DENV NS1 mAb. Data are the mean 6 SD of three
independent experiments as described in Figure 6.
doi:10.1371/journal.ppat.0030183.g007
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Mechanism NS1 Attachment to Cellssalt gradient (0–1 M NaCl) over 20-column volumes at 1 ml/min.
Purity and immunoreactivity of DENV NS1 were conﬁrmed by SDS-
PAGE with silver staining and western blot. Concentrations of
puriﬁed protein were determined by the bicinchoninic acid assay.
Puriﬁed DENV NS1 from DENV-infected mammalian cells was
obtained as previously described [28].
DENV NS1 binding to cells. Adherent cells were removed from
tissue culture plates after incubation with an EDTA solution (4 mM
EDTA plus 10% FBS in PBS). Cells (5 3 10
5) in suspension were
incubated on ice for 1 h with 100 ll of puriﬁed DENV NS1 at
indicated concentrations or 300 ll of serum-free supernatants from
BHK DENV-2 Rep cells. After washing once with 3 ml of medium, 50
ll of DENV-2 NS1 speciﬁc mAb 2G6 (25 lg/ml) or an isotype-matched
negative control mAb was added to the cells and incubated on ice for
45 min. After subsequent washing, bound primary mAbs were
detected after 30-min incubation with a 1:500 dilution of Alexa
Fluor 647-conjugated anti-mouse IgG (Invitrogen). Of note, experi-
ments were also performed in parallel with serial washing steps and
no signiﬁcant difference in binding or background was observed.
Propidium iodide (0.2 mg/ml) was added immediately before ﬂow
cytometry to exclude dead cells.
Soluble GAG and DENV NS1 competitive binding assays. Cell
suspensions were incubated with DENV NS1 in the presence or
absence of varying concentrations of soluble GAG for 1 h on ice.
Bound DENV NS1 was detected after antibody staining as described
above and analyzed by ﬂow cytometry.
Enzymatic digestion of GAGs from cellular surfaces. Cell suspen-
sions were centrifuged at 200 x g for 2 min and were resuspended in
PBS containing 0.1% BSA. Heparin lyases I, II, III (0.06 U/ml ﬁnal
concentration) or chondroitinase ABC (0.1 U/ml ﬁnal concentration)
was added to a 50-ll of cell suspension and incubated at 37 8Ci na
shaking incubator for 1 h. After three washes with cold DMEM, the
cells were incubated sequentially with DENV NS1 and DENV NS1
mAbs and analyzed by ﬂow cytometry.
Quantiﬁcation of surface GAG levels. Different types of CHO cells
were cultured as described above. CHO cells were rinsed and
detached from cell culture dishes after incubation in PBS/EDTA for
15 min. Cells (10
7) were treated with 2 ml trypsin-EDTA (1X solution,
Mediatech) at 37 8C for 10 min, which released cell surface
proteoglycans. These were collected and used for cell surface GAG
isolation and quantiﬁcation by high-pressure liquid chromatography
as reported previously [51].
DENV NS1 and GAG binding ELISA. Maxi-Sorp microtiter plates
(Nalge Nunc International) were adsorbed with soluble GAG (1 mg/ml
in PBS) at 4 8C overnight. After four washes with PBS (300 ll/well),
nonspeciﬁc binding sites were blocked with 1% heat-inactivated (65
8C, 15 min) BSA in PBS for 2 h at 37 8C and followed by ﬁve washes
with PBS. Clariﬁed serum-free supernatants from BHK or BHK
DENV-2 Rep cells (100 ll diluted 1:1 in PBS) were added to each well
and incubated for 2 h at room temperature. Plates were then washed
ﬁve times with PBS containing 0.05% Tween-20 followed by a 1-h
incubation at room temperature with 100 ll of puriﬁed DENV NS1
speciﬁc mAb mixtures (1A4, 1B2, 1F11, 2G6, and 2E3; 1 lg/ml of each
Figure 8. Binding of DENV NS1 to Mouse Tissues
Cryo-sections of mouse (A) lung, (B) liver, and (C) intestine were
incubated with serum-free supernatants from BHK DENV-2 Rep or BHK
cells for 1 h at room temperature. After extensive washing, bound NS1
was detected by a mixture of NS1 mAbs (1A4, 1F11, 2G6, 1B2) followed
by Cy3-conjugated goat anti-mouse IgG. Co-staining with endothelial
cell marker was subsequently performed by incubating the sections with
rat anti-mouse CD31 (PECAM-1) followed by Alexa Fluor 488-conjugated
goat anti-rat IgG. Nuclei were stained with a DNA-specific dye TO-PRO-3.
Sections incubated with DENV NS1 followed by an isotype control Ab
served as a negative control. Analysis was performed by confocal
microscopy. White arrow and yellow arrowhead denote the layer of
endothelial cells in the lumen and the outer layer of the adventitia of
pulmonary vessel, respectively.
doi:10.1371/journal.ppat.0030183.g008
Figure 9. Binding of DENV NS1 to Human Lung
Cryo-sections of human lung tissue were incubated with 20 lg/ml of
purified DENV-2 NS1 or BSA for 1 h at room temperature. Bound NS1 was
detected by staining with a mixture of DENV NS1 mAbs (1A4, 1F11, 2G6,
1B2) followed by Alexa Fluor 488 conjugated with goat anti-mouse IgG.
Subsequently, the sections were co-stained with rabbit anti-human CD31
(PECAM-1) followed by Cy3-conjugated donkey anti-rabbit IgG. Nuclei
were stained with a DNA-specific dye (Hoechst) and the sections were
analyzed by confocal microscopy. Sections incubated with purified DENV
NS1 and stained with isotype mAbs served as a negative control.
doi:10.1371/journal.ppat.0030183.g009
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mouse IgG (1 lg/ml) and horseradish peroxidase-conjugated strepta-
vidin were added sequentially for 1-h incubations at room temper-
ature. After six ﬁnal washes with PBS, signal was detected by adding
150 ll of TMB substrate (DakoCytomation) and 50 ll of 0.1 N H2SO4
stop solution to each well. Plates were evaluated at 450 nm on a 96-
well plate reader (Genios Pro; Tecan Instruments).
Sodium chlorate treatment of cell cultures. Sulfation was inhibited
by sodium chlorate treatment [56]. BHK and CHO cells were cultured
in sulfate-free Joklik Modiﬁcation Minimum Essential Medium Eagle
(Sigma) or Ham’s F12 medium (Tissue culture support center,
Washington University) supplemented with 10% dialyzed FBS
(Sigma) containing different concentrations (1–75 mM) of sodium
chlorate. In some experiments, 10 mM sodium sulfate was added to
replenish sulfate to the cells. After overnight culture, cells were
processed for DENV NS1 binding as described above.
Analysis of NS1 expression on the surface of DENV-infected cells.
BHK cells (1.6 3 10
5/well) were seeded onto 12-well tissue culture
plate (Costar). 24 h later, cells were infected with DENV-2 (strain
16681) at a multiplicity of infection (MOI) of 3. After a 2-h incubation
at 37 8C, cell monolayers were extensively washed and cultured in
DMEM containing 4% FBS. In some experiments, DENV-infected
cells were cultured in medium containing 1, 10, or 100 lg/ml of HP or
CS-C or 25 mM sodium chlorate. At speciﬁc intervals post-infection,
cells were harvested from culture plates with an EDTA solution (4
mM EDTA plus 10% FBS in PBS). DENV NS1 on the surface was
determined by incubation of 5310
5 cells with anti-DENV-2 NS1 mAb
clone 2G6 or mouse polyclonal anti-DENV-2 NS1 (20 lg/ml ﬁnal
concentration) for 1 h at 4 8C. After three washes, cells were
incubated with Alexa Fluor 647-conjugated anti-mouse IgG (1:500)
and analyzed by ﬂow cytometry. In some experiments, DENV-
infected cells were treated with a mix of heparin lyases I, II, III or
chondroitinase ABC prior to detection of surface NS1.
DENV NS1 binding to tissues. Human lung tissue: The protocol to
obtain human lung tissues from patients was approved by the
Institutional Review Board at the Faculty of Medicine Siriraj
Hospital, Mahidol University. A human lung, surgically removed with
informed consent from a patient with lung cancer, was evaluated
macroscopically for cancer-free regions. Selected tissues, cut from the
central part of the cancer-free region of the lung, were cryoprotected
in 30% sucrose for generation of 6- to 7-lm frozen sections.
Cryosections were thawed, ﬁxed in 4% paraformaldehyde (Sigma)
in PBS at room temperature for 10 min, and washed extensively with
PBS. Tissues were incubated with puriﬁed DENV NS1 or BSA at 20
lg/ml for 1 h at room temperature and followed by three washes with
0.1% BSA in PBS 5 min each. Sections were incubated with a mixture
of mAbs (1A4, 1F11, 2G6, 1B2; 20 lg/ml ﬁnal concentration) against
DENV NS1. A mixture of IgG1 (MOPC-21, Sigma) and IgG2a (UPC-10,
Sigma) at 20 lg/ml was used as isotype control Abs. After three
washes, sections were incubated with Alexa Fluor 488 conjugated goat
anti-mouse IgG secondary antibody (Invitrogen) and followed by 1-h
incubation at room temperature with rabbit anti-human CD31
(PECAM) (Santa Cruz Biotechnology) at the dilution of 1:10. Sections
were washed three times and incubated with Cy3 conjugated donkey
anti-rabbit IgG (Jackson Immuno Research Laboratories). Nuclear
staining was achieved by incubation for 15 min with 1:100 dilution of
Hoechst dye (Invitrogen) and visualized using a Zeiss 510 Meta LSM
confocal microscope.
Mouse tissues: To obtain tissues from mice, 4- to 6-wk-old
uninfected C57BL/6 mice were anesthesized with ketamine and
xylazine and perfused with 20 ml of PBS. Tissues were dissected and
cryoprotected in 30% sucrose for generation of frozen sections.
Serial 6-lm cryosections were air-dried for 1 h at room temperature
followed by washing with PBS. Sections were ﬁxed with 50% acetone
in PBS for 10 min on ice, incubated with PBS containing 2 M NaCl
(pH 7.4) for 10 min at room temperature, and blocked in PBS
containing 0.5% BSA for 1 h at room temperature or overnight at 4
8C. Subsequently, sections were incubated with serum-free super-
natants from BHK DENV-2 Rep or BHK cells for 1 h at room
temperature followed by incubation with a mixture of anti-NS1-
mAbs (1A4, 1F11, 2G6, 1B2; 10 lg/ml ﬁnal concentration) or isotype
control mAbs (10 lg/ml) diluted in PBS containing 0.5% BSA. After
three washes, sections were incubated with Cy3 conjugated with goat
anti-mouse IgG (Zymed) at the dilution of 1:200. Co-staining with
endothelial cell marker, CD31 (PECAM), was accomplished by a 1-h
incubation with rat anti-mouse PECAM-1 (CD31) (BD Pharmingen) at
a dilution of 1:250 followed by incubation with a 1:500 dilution of
secondary Alexa Fluor 488 conjugated anti-rat IgG (Invitrogen).
Nuclear staining was achieved by incubation for 15 min with 1:2,500
dilution of TO-Pro-3 (Invitrogen). Sections were mounted using
ﬂuorescent mounting medium (Vector Laboratories) and analyzed
using a Zeiss 510 Meta LSM confocal microscope. For soluble GAGs
and DENV NS1 competitive binding experiments, serum-free super-
natants from BHK DENV-2 Rep were mixed with soluble CS-C, CS-E,
or HP (3.3 lM ﬁnal concentration) prior to incubation with sections
of mouse lung. The sections were further processed for DENV NS1
and CD31 staining as described above. 50–60 images of each
condition were captured by confocal microscopy, and ﬂuorescent
intensity of each image was analyzed using the Volocity software
(Improvision). Regions that stained positively for CD31 (intensity
greater than 427 arbitrary units on the intensity scale of 0–4,095)
were selected for analysis. Mean intensity of DENV NS1 binding was
calculated for all measured regions. For analysis of DENV NS1
binding to pleura, regions were manually selected based on
anatomical sites at the surface of the lung.
Statistical analysis. Datasets were compared by a two-tailed,
unpaired t test. Multiple comparisons were performed using an
ANOVA test. Statistical signiﬁcance was achieved when p-values were
, 0.05. Data analysis was performed using Prism software (Graph-
Pad).
Supporting Information
Figure S1. Immunoreactivity of Puriﬁed DENV-2 NS1 with mAbs
Puriﬁed NS1 from BHK DENV-2 Rep cells (rNS1) or DENV-2 infected
cells (iNS1) (250 ng/well) was maintained at room temperature or
heated (at 95 8C for 5 min) in SDS nonreducing sample buffer
immediately prior to 12% SDS-PAGE. Western blot was performed
with the individual NS1-speciﬁc mAbs 2E11, 2E3, 1F11, 2G6, 1A4, and
1B2. Monomer and dimer forms of NS1 are indicated.
Found at doi:10.1371/journal.ppat.0030183.sg001 (1.5 MB TIF).
Figure S2. Binding of DENV NS1 to Mesothelial Cells Lining Pleura
and Peritoneum
Cryo-sections of mouse (A) lung, (B) intestine were incubated with
serum-free supernatants from BHK DENV-2 Rep or BHK cells for 1 h
at room temperature. After extensive washing, bound NS1 was
detected by a mixture of NS1 mAbs (1A4, 1F11, 2G6, 1B2) followed by
Cy3-conjugated goat anti-mouse IgG. Costaining with endothelial cell
marker was subsequently performed by incubating the sections with
rat anti-mouse CD31 (PECAM) followed by Alexa Fluor 488-
conjugated goat anti-rat IgG. Nuclei were stained with a DNA-
speciﬁc dye TO-Pro-3. Sections incubated with DENV NS1 followed
by an isotype control Ab served as a negative control. Analysis was
performed by confocal microscopy. Arrowheads denote a single layer
of mesothelial cells lining pleura (A) or peritoneum (B).
Found at doi:10.1371/journal.ppat.0030183.sg002 (38.7 MB TIF).
Acknowledgments
We thank H. Liapis for reviewing the results of NS1 binding on tissues
and R. Hauhart, S. Thiemmeca, S. Noisakran, M. Samuel, K. Liszewski,
J. Price, A. Fuchs, C. Kemper, D. Spitzer, X. Wu, P. Bertram, D. Gill,
and W. Beatty for experimental help and advice.
Author contributions. PA and LZ conceived, designed, and
performed experiments. NP, AM, CP, WK, PM, JPA, and MSD
conceived and designed experiments. PA, LZ, PM, JPA, and MSD
wrote the paper.
Funding. This work was supported by a Burroughs Wellcome Fund
Clinical Translational Award to MSD; the National Center for
Genetic Engineering and Biotechnology (BIOTEC), Thailand to PA
and PM; the Senior Research Scholar Program of the Thailand
Research Fund TRF to PM; the National Institutes of Health
(GM069968) to LZ; and the Midwest Regional Centers for Excellence
for Biodefense and Emerging Infectious Disease Research (U54-
AI057160) to JPA and MSD. PA has been supported by an NIH
postdoctoral training grant from the Division of Dermatology of the
Department of Medicine, Washington University School of Medicine
and a pre-clinical grant from the Faculty of Medicine Siriraj Hospital,
Mahidol University.
Competing interests. The authors have declared that no competing
interests exist.
PLoS Pathogens | www.plospathogens.org November 2007 | Volume 3 | Issue 11 | e183 1810
Mechanism NS1 Attachment to CellsReferences
1. Gubler DJ (2002) Epidemic dengue/dengue hemorrhagic fever as a public
health, social, and economic problem in the 21st century. Trends Microbiol
10: 100–103.
2. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S,
et al. (1984) Risk factors in dengue shock syndrome: a prospective
epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J
Epidemiol 120: 653–669.
3. Guzman MG, Kouri G, Valdes L, Bravo J, Alvarez M, et al. (2000)
Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am J
Epidemiol 152:: 793–799; discussion 804.
4. Nimmannitya S (1987) Clinical spectrum and management of dengue
haemorrhagic fever. Southeast Asian J Trop Med Public Health 18: 392–
397.
5. Rothman AL, Ennis FA (1999) Immunopathogenesis of dengue hemor-
rhagic fever. Virology 257: 1–6.
6. Rothman AL (2004) Dengue: deﬁning protective versus pathologic
immunity. J Clin Invest 113: 946–951.
7. Halstead SB (1988) Pathogenesis of dengue: challenges to molecular
biology. Science 239: 476–481.
8. Halstead SB, O’Rourke EJ (1977) Dengue viruses and mononuclear
phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp
Med 146: 201–217.
9. Kliks SC, Nimmanitya S, Nisalak A, Burke DS (1988) Evidence that maternal
dengue antibodies are important in the development of dengue hemor-
rhagic fever in infants. Am J Trop Med Hyg 38: 411–419.
10. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS (1989) Antibody-
dependent enhancement of dengue virus growth in human monocytes as a
risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40: 444–
451.
11. Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, et al. (2002)
High circulating levels of the dengue virus nonstructural protein NS1 early
in dengue illness correlate with the development of dengue hemorrhagic
fever. J Infect Dis 186: 1165–1168.
12. Murgue B, Roche C, Chungue E, Deparis X (2000) Prospective study of the
duration and magnitude of viraemia in children hospitalized during the
1996–1997 dengue-2 outbreak in French Polynesia. J Med Virol 60: 432–
438.
13. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, et al.
(2000) Dengue viremia titer, antibody response pattern, and virus serotype
correlate with disease severity. J Infect Dis 181: 2–9.
14. Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I, et al. (1999)
Dengue virus structural differences that correlate with pathogenesis. J Virol
73: 4738–4747.
15. Cologna R, Rico-Hesse R (2003) American genotype structures decrease
dengue virus output from human monocytes and dendritic cells. J Virol 77:
3929–3938.
16. Pryor MJ, Carr JM, Hocking H, Davidson AD, Li P, et al. (2001) Replication
of dengue virus type 2 in human monocyte-derived macrophages:
comparisons of isolates and recombinant viruses with substitutions at
amino acid 390 in the envelope glycoprotein. Am J Trop Med Hyg 65: 427–
434.
17. Watts DM, Porter KR, Putvatana P, Vasquez B, Calampa C, et al. (1999)
Failure of secondary infection with American genotype dengue 2 to cause
dengue haemorrhagic fever. Lancet 354: 1431–1434.
18. Messer WB, Vitarana UT, Sivananthan K, Elvtigala J, Preethimala LD, et al.
(2002) Epidemiology of dengue in Sri Lanka before and after the
emergence of epidemic dengue hemorrhagic fever. Am J Trop Med Hyg
66: 765–773.
19. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, et
al. (1999) Elevated plasma interleukin-10 levels in acute dengue correlate
with disease severity. J Med Virol 59: 329–334.
20. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, et
al. (1999) Early immune activation in acute dengue illness is related to
development of plasma leakage and disease severity. J Infect Dis 179: 755–
762.
21. Hober D, Poli L, Roblin B, Gestas P, Chungue E, et al. (1993) Serum levels of
tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and inter-
leukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg
48: 324–331.
22. Hober D, Delannoy AS, Benyoucef S, De Groote D, Wattre P (1996) High
levels of sTNFR p75 and TNF alpha in dengue-infected patients. Microbiol
Immunol 40: 569–573.
23. Hober D, Nguyen TL, Shen L, Ha DQ, Huong VT, et al. (1998) Tumor
necrosis factor alpha levels in plasma and whole-blood culture in dengue-
infected patients: relationship between virus detection and pre-existing
speciﬁc antibodies. J Med Virol 54: 210–218.
24. Bethell DB, Flobbe K, Cao XT, Day NP, Pham TP, et al. (1998)
Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic
fever. J Infect Dis 177: 778–782.
25. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangth-
awornchaikul N, et al. (2003) Original antigenic sin and apoptosis in the
pathogenesis of dengue hemorrhagic fever. Nat Med 9: 921–927.
26. Mongkolsapaya J, Duangchinda T, Dejnirattisai W, Vasanawathana S,
Avirutnan P, et al. (2006) T cell responses in dengue hemorrhagic fever:
are cross-reactive T cells suboptimal? J Immunol 176: 3821–3829.
27. Bashyam HS, Green S, Rothman AL (2006) Dengue virus-reactive CD8þ T
cells display quantitative and qualitative differences in their response to
variant epitopes of heterologous viral serotypes. J Immunol 176: 2817–
2824.
28. Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, et al.
(2006) Vascular leakage in severe dengue virus infections: a potential role
for the nonstructural viral protein NS1 and complement. J Infect Dis 193:
1078–1088.
29. Lindenbach BD, Rice CM (1999) Genetic interaction of ﬂavivirus non-
structural proteins NS1 and NS4A as a determinant of replicase function. J
Virol 73: 4611–4621.
30. Mackenzie JM, Jones MK, Young PR (1996) Immunolocalization of the
dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA
replication. Virology 220: 232–240.
31. Winkler G, Maxwell SE, Ruemmler C, Stollar V (1989) Newly synthesized
dengue-2 virus nonstructural protein NS1 is a soluble protein but becomes
partially hydrophobic and membrane-associated after dimerization.
Virology 171: 302–305.
32. Flamand M, Megret F, Mathieu M, Lepault J, Rey FA, et al. (1999) Dengue
virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian
cells as a soluble hexamer in a glycosylation-dependent fashion. J Virol 73:
6104–6110.
33. Alcon S, Talarmin A, Debruyne M, Falconar A, Deubel V, et al. (2002)
Enzyme-linked immunosorbent assay speciﬁc to dengue virus type 1
nonstructural protein NS1 reveals circulation of the antigen in the blood
during the acute phase of disease in patients experiencing primary or
secondary infections. J Clin Microbiol 40: 376–381.
34. Young PR, Hilditch PA, Bletchly C, Halloran W (2000) An antigen capture
enzyme-linked immunosorbent assay reveals high levels of the dengue virus
protein NS1 in the sera of infected patients. J Clin Microbiol 38: 1053–1057.
35. Falconar AK (1997) The dengue virus nonstructural-1 protein (NS1)
generates antibodies to common epitopes on human blood clotting,
integrin/adhesin proteins and binds to human endothelial cells: potential
implications in haemorrhagic fever pathogenesis. Arch Virol 142: 897–916.
36. Chang HH, Shyu HF, Wang YM, Sun DS, Shyu RH, et al. (2002) Facilitation
of cell adhesion by immobilized dengue viral nonstructural protein 1 (NS1):
arginine-glycine-aspartic acid structural mimicry within the dengue viral
NS1 antigen. J Infect Dis 186: 743–751.
37. Lin CF, Lei HY, Shiau AL, Liu HS, Yeh TM, et al. (2002) Endothelial cell
apoptosis induced by antibodies against dengue virus nonstructural
protein 1 via production of nitric oxide. J Immunol 169: 657–664.
38. Lin CF, Lei HY, Shiau AL, Liu CC, Liu HS, et al. (2003) Antibodies from
dengue patient sera cross-react with endothelial cells and induce damage. J
Med Virol 69: 82–90.
39. Lin CF, Chiu SC, Hsiao YL, Wan SW, Lei HY, et al. (2005) Expression of
cytokine, chemokine, and adhesion molecules during endothelial cell
activation induced by antibodies against dengue virus nonstructural
protein 1. J Immunol 174: 395–403.
40. Alcon-LePoder S, Drouet MT, Roux P, Frenkiel MP, Arborio M, et al. (2005)
The secreted form of dengue virus nonstructural protein NS1 is
endocytosed by hepatocytes and accumulates in late endosomes: implica-
tions for viral infectivity. J Virol 79: 11403–11411.
41. Chung KM, Liszewski MK, Nybakken G, Davis AE, Townsend RR, et al.
(2006) West Nile virus nonstructural protein NS1 inhibits complement
activation by binding the regulatory protein factor H. Proc Natl Acad Sci U
S A 103: 19111–19116.
42. Wright PJ, Cauchi MR, Ng ML (1989) Deﬁnition of the carboxy termini of
the three glycoproteins speciﬁed by dengue virus type 2. Virology 171: 61–
67.
43. Jacobs MG, Robinson PJ, Bletchly C, Mackenzie JM, Young PR (2000)
Dengue virus nonstructural protein 1 is expressed in a glycosyl-phospha-
tidylinositol-linked form that is capable of signal transduction. FASEB J 14:
1603–1610.
44. Schlesinger JJ, Brandriss MW, Putnak JR, Walsh EE (1990) Cell surface
expression of yellow fever virus nonstructural glycoprotein NS1: con-
sequences of interaction with antibody. J Gen Virol 71 (Pt 3): 593–599.
4 5 . W h i t b yK ,P i e r s o nT C ,G e i s sB ,L a n eK ,E n g l eM ,e ta l .( 2 0 0 5 )
Castanospermine, a potent inhibitor of dengue virus infection in vitro
and in vivo. J Virol 79: 8698–8706.
46. Esko JD, Stewart TE, Taylor WH (1985) Animal cell mutants defective in
glycosaminoglycan biosynthesis. Proc Natl Acad Sci U S A 82: 3197–3201.
47. Broekelmann TJ, Kozel BA, Ishibashi H, Werneck CC, Keeley FW, et al.
(2005) Tropoelastin interacts with cell-surface glycosaminoglycans via its
COOH-terminal domain. J Biol Chem 280: 40939–40947.
48. Zhang L, Lawrence R, Frazier BA, Esko JD (2006) CHO glycosylation
mutants: proteoglycans. Methods Enzymol 416: 205–221.
49. Zhang L, Beeler DL, Lawrence R, Lech M, Liu J, et al. (2001) 6-O-
sulfotransferase-1 represents a critical enzyme in the anticoagulant
heparan sulfate biosynthetic pathway. J Biol Chem 276: 42311–42321.
50. Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, et al. (1999) A novel role
for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99:
13–22.
51. Studelska DR, Giljum K, McDowell LM, Zhang L (2006) Quantiﬁcation of
PLoS Pathogens | www.plospathogens.org November 2007 | Volume 3 | Issue 11 | e183 1811
Mechanism NS1 Attachment to Cellsglycosaminoglycans by reversed-phase HPLC separation of ﬂuorescent
isoindole derivatives. Glycobiology 16: 65–72.
52. Kinoshita A, Yamada S, Haslam SM, Morris HR, Dell A, et al. (1997) Novel
tetrasaccharides isolated from squid cartilage chondroitin sulfate E contain
unusual sulfated disaccharide units GlcA(3-O-sulfate)beta1-3GalNAc(6-O-
sulfate) or GlcA(3-O-sulfate)beta1-3GalNAc. J Biol Chem 272: 19656–19665.
53. Turnbull J, Powell A, Guimond S (2001) Heparan sulfate: decoding a
dynamic multifunctional cell regulator. Trends Cell Biol 11: 75–82.
54. Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L (1997) Heparan
sulfate proteoglycans of the cardiovascular system. Speciﬁc structures
emerge but how is synthesis regulated? J Clin Invest 99: 2062–2070.
55. Hileman RE, Fromm JR, Weiler JM, Linhardt RJ (1998) Glycosaminoglycan-
protein interactions: deﬁnition of consensus sites in glycosaminoglycan
binding proteins. Bioessays 20: 156–167.
56. Baeuerle PA, Huttner WB (1986) Chlorate: a potent inhibitor of protein
sulfation in intact cells. Biochem Biophys Res Commun 141: 870–877.
57. Bhamarapravati N, Tuchinda P, Boonyapaknavik V (1967) Pathology of
Thailand haemorrhagic fever: a study of 100 autopsy cases. Ann Trop Med
Parasitol 61: 500–510.
58. Jessie K, Fong MY, Devi S, Lam SK, Wong KT (2004) Localization of dengue
virus in naturally infected human tissues by immunohistochemistry and in
situ hybridization. J Infect Dis 189: 1411–1418.
59. Esko JD, Selleck SB (2002) Order out of chaos: assembly of ligand binding
sites in heparan sulfate. Annu Rev Biochem 71: 435–471.
60. Bishop JR, Schuksz M, Esko JD (2007) Heparan sulphate proteoglycans ﬁne-
tune mammalian physiology. Nature 446: 1030–1037.
61. Xia G, Chen J, Tiwari V, Ju W, Li JP, et al. (2002) Heparan sulfate 3-O-
sulfotransferase isoform 5 generates both an antithrombin-binding site and
an entry receptor for herpes simplex virus, type 1. J Biol Chem 277: 37912–
37919.
62. Bergefall K, Trybala E, Johansson M, Uyama T, Naito S, et al. (2005)
Chondroitin sulfate characterized by the E-disaccharide unit is a potent
inhibitor of herpes simplex virus infectivity and provides the virus binding
sites on gro2C cells. J Biol Chem 280: 32193–32199.
63. Noisakran S, Dechtawewat T, Rinkaewkan P, Puttikhunt C, Kanjanahalue-
thai A, et al. (2007) Characterization of dengue virus NS1 stably expressed
in 293T cell lines. J Virol Methods 142: 67–80.
64. Turnbull J, Drummond K, Huang Z, Kinnunen T, Ford-Perriss M, et al.
(2003) Heparan sulphate sulphotransferase expression in mice and
Caenorhabditis elegans. Biochem Soc Trans 31: 343–348.
65. Zhang L, Schwartz JJ, Miller J, Liu J, Fritze LM, et al. (1998) The retinoic
acid and cAMP-dependent up-regulation of 3-O-sulfotransferase-1 leads to
a dramatic augmentation of anticoagulantly active heparan sulfate biosyn-
thesis in F9 embryonal carcinoma cells. J Biol Chem 273: 27998–28003.
66. Rot A, Hub E, Middleton J, Pons F, Rabeck C, et al. (1996) Some aspects of
IL-8 pathophysiology. III: Chemokine interaction with endothelial cells. J
Leukoc Biol 59: 39–44.
67. Witt DP, Lander AD (1994) Differential binding of chemokines to
glycosaminoglycan subpopulations. Curr Biol 4: 394–400.
68. Avirutnan P, Malasit P, Seliger B, Bhakdi S, Husmann M (1998) Dengue
virus infection of human endothelial cells leads to chemokine production,
complement activation, and apoptosis. J Immunol 161: 6338–6346.
69. Puttikhunt C, Kasinrerk W, Srisa-ad S, Duangchinda T, Silakate W, et al.
(2003) Production of anti-dengue NS1 monoclonal antibodies by DNA
immunization. J Virol Methods 109: 55–61.
70. Duncan MB, Chen J, Krise JP, Liu J (2004) The biosynthesis of anticoagulant
heparan sulfate by the heparan sulfate 3-O-sulfotransferase isoform 5.
Biochim Biophys Acta 1671: 34–43.
71. Pegtel DM, Middeldorp J, Thorley-Lawson DA (2004) Epstein-Barr virus
infection in ex vivo tonsil epithelial cell cultures of asymptomatic carriers. J
Virol 78: 12613–12624.
72. Pattanapanyasat K, Noulsri E, Fucharoen S, Lerdwana S, Lamchiagdhase P,
et al. (2004) Flow cytometric quantitation of red blood cell vesicles in
thalassemia. Cytometry B Clin Cytom 57: 23–31.
73. Diamond MS, Edgil D, Roberts TG, Lu B, Harris E (2000) Infection of
human cells by dengue virus is modulated by different cell types and viral
strains. J Virol 74: 7814–7823.
74. Lawrence R, Kuberan B, Lech M, Beeler DL, Rosenberg RD (2004) Mapping
critical biological motifs and biosynthetic pathways of heparan sulfate.
Glycobiology 14: 467–479.
75. Liu J, Shriver Z, Pope RM, Thorp SC, Duncan MB, et al. (2002)
Characterization of a heparan sulfate octasaccharide that binds to herpes
simplex virus type 1 glycoprotein D. J Biol Chem 277: 33456–33467.
PLoS Pathogens | www.plospathogens.org November 2007 | Volume 3 | Issue 11 | e183 1812
Mechanism NS1 Attachment to Cells